Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home AI & Quantum Computing

Quantum Computing Stock Faces Sharp Reversal After Analyst Downgrade

Dieter Jaworski by Dieter Jaworski
November 4, 2025
in AI & Quantum Computing, Analysis, Tech & Software, Trading & Momentum
0
Rigetti Stock
0
SHARES
24
VIEWS
Share on FacebookShare on Twitter

The quantum computing sector experienced significant turbulence as Rigetti shares underwent a dramatic reversal following an unexpected analyst rating change. After climbing an impressive 190% since the beginning of the year, the stock’s upward trajectory came to an abrupt halt when market researchers issued a sobering reassessment of its valuation.

Market Reaction to Rating Adjustment

Investment firm B. Riley Securities triggered the sell-off by downgrading Rigetti from “Buy” to “Neutral,” indicating they no longer recommend purchasing the stock at current price levels. The market response was immediate and severe, with shares plunging more than 11% and snapping a three-day winning streak. Trading activity surged dramatically, reaching $2.39 billion in volume and securing the company’s position as the 32nd most actively traded security for the session.

Valuation Concerns Emerge

In a seemingly contradictory move, B. Riley analysts simultaneously raised their price target from $35 to $42 per share. However, the stock’s market price had already surpassed this revised target, suggesting experts believe the company’s growth potential is already fully reflected in its current valuation.

Should investors sell immediately? Or is it worth buying Rigetti?

Several factors underpin these valuation concerns:

  • The company’s $14.3 billion market capitalization already accounts for a substantial portion of the total market projected for 2030-2035
  • Potential delays in U.S. government contracts could jeopardize future revenue streams
  • With a price-to-book ratio of 25.94, Rigetti ranks among the most expensive stocks in its sector

Operational Strength Amid Market Skepticism

Despite the downgrade, Rigetti’s underlying business operations demonstrate resilience. The company maintains quarterly cash burn of approximately $19 million, which remains well-covered by liquid assets totaling $572 million. Additionally, the quantum computing specialist recently secured a $5.8 million contract from the U.S. Air Force Research Laboratory, providing near-term revenue validation.

Investors await the next critical test of the company’s valuation thesis when Rigetti reports third-quarter results on November 10. These financial figures will likely determine whether the current premium valuation remains justified or if further market adjustments lie ahead.

Ad

Rigetti Stock: Buy or Sell?! New Rigetti Analysis from February 8 delivers the answer:

The latest Rigetti figures speak for themselves: Urgent action needed for Rigetti investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 8.

Rigetti: Buy or sell? Read more here...

Tags: Rigetti
Dieter Jaworski

Dieter Jaworski

About Dieter Jaworski From a numbers-obsessed child to creating his first investment newsletter. Even as a child, Dieter Jaworski's mother couldn't believe how fascinated he was with numbers. This early passion for mathematics and data analysis laid the foundation for a successful career in financial markets and investment analysis.
Areas of Expertise:
  • Quantitative Analysis
  • Financial Newsletter Publishing
  • Data-Driven Investment Strategies
  • Market Pattern Recognition
Dieter's unique approach combines his natural affinity for numbers with decades of market experience, providing investors with data-driven insights and practical investment strategies.

Related Posts

Quanterix Stock
Analysis

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026
Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Repay Holdings Stock
Analysis

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Next Post
Assembly Biosciences Stock

Is Assembly Biosciences Nearing a Critical Inflection Point?

SunHydrogen Stock

SunHydrogen Shares Face Unrelenting Downtrend

Warner Bros. Discovery (A) Stock

Media Giant Warner Bros. Discovery Navigates Billion-Dollar Crossroads

Recommended

Biotechnology Stock Exchange

Analysts Bullish on Dynatrace with Price Targets on the Rise

2 years ago
The Trade Desk Stock

The Trade Desk Faces Mounting Pressure as Amazon Strikes Netflix Deal

5 months ago

Analyst Reaffirms Buy Rating on International Seaways with 66 Price Target

2 years ago
Biotechnology Stock Bull Market

KeyBanc Analyst Raises Price Target and Maintains Overweight Rating on Repligen NASDAQ RGEN

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

Repay Holdings: Annual Report to Test Strategic Refinancing Success

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Trending

Puma Biotechnology Stock
Earnings

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

by Jackson Burston
February 8, 2026
0

Investor attention is now firmly fixed on February 26, 2026, as Puma Biotechnology prepares to release its...

Quanterix Stock

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026
Design Therapeutics Stock

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Puma Biotechnology Sets Date for Full-Year Financial Disclosure
  • Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test
  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com